Andrew Cornforth

Chief Technology Officer with over 15 years of leadership in biopharmaceutical development, specializing in process and analytical development, CAR-T and lentiviral vector manufacturing, and, most recently, mRNA delivered immune modulators. Proven track record in scaling innovative drug development processes from bench-scale to clinical trials, while ensuring regulatory compliance and quality control. Expertise spans GMP operations, CMC strategy, and clinical logistics, with experience driving cross-functional teams, managing multi-million-dollar budgets, and leading partnerships with major biotech firms. A seasoned entrepreneur, having co-founded AIVITA Biomedical and successfully led complex manufacturing and development programs. Strong background in business development, investor relations, and regulatory filings, contributing to successful funding rounds and IND submissions. Committed to advancing scientific innovation through leadership, strategic vision, and a dedication to excellence.